Translate
Vaxcyte, Inc.
About
Vaxcyte, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 7 2026
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
Mar 23 2026
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Mar 18 2026
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Feb 24 2026
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Feb 11 2026
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
Recent Videos
Vaxcyte (PCVX) Stock Analysis 2026: Zero Revenue, $8B Valuation & 200% Returns
May 01, 2026
How to Invest in Vaxcyte Inc (PCVX) Step by Step
Mar 01, 2026
Vaxcyte, Inc. (PCVX) #HealthcareStocks #VaccineStock #VaccineDevelopment #BiotechStocks
Feb 28, 2026
Vaxcyte Q4 2025 Earnings Call
Feb 25, 2026